Implant-Associated Cancers: A Look Beyond BIA-ALCL
Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
Bing-Neel Syndrome: Managing Patients With Waldenström Macroglobulinemia Characterized by CNS Involvement
According to the authors, treatment of patients with Bing-Neel syndrome should involve the use of CNS-penetrating approaches.
Real-World Outcomes With Ibrutinib in Waldenström Macroglobulinemia
A study of real-world patients with Waldenström macroglobulinemia revealed that ibrutinib monotherapy was linked to efficacy — but also toxicity.
No Benefit With Upfront Rituximab and Autologous HSCT Consolidation for Aggressive Non-Hodgkin Lymphomas
Researchers conducted a meta-analysis of studies evaluating survival outcomes with rituximab plus chemotherapy with or without autologous HSCT.
Incidence of GI Adverse Events Associated With CAR-T Therapy for Lymphoma or Leukemia Is Low
A retrospective evaluation of patients with leukemia or lymphoma treated with CAR-T therapy determined their likelihood of experiencing refractory colitis associated with the treatment.
Use of Interim PET/CT to Stratify Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Patients with positive interim PET/CT demonstrated poorer overall and progression-free survival compared with patients with negative interim PET/CT.
M7-FLIPI Score Not Predictive of Outcomes in Chemo-Free Regimens for Follicular Lymphoma
Researchers did not find a significant difference in survival outcomes for high- and low-risk patients with follicular lymphoma receiving immunotherapy.
Newly Identified Mutation May Result in Venetoclax Resistance in Follicular Lymphoma
Further investigations should look at the role of acquired BCL2 mutations in venetoclax resistance.
Germline BRCA2 Mutations Linked to Pediatric Lymphomas
Survivors of NHL should be offered genetic counseling.
Genetic Overlap Between Autoimmune Disease and NHL Not Supported by Genome-Wide Association Study
Researchers hypothesized that overlapping characteristics between autoimmune disease and NHL could be the result of similar genetic components.
Efficacy of 19-28z CAR-T in DLBCL Unclear: Phase 1 Study Readout
The investigational treatment was associated with a high rate of neurotoxicity.
Rituximab Upfront Therapy and Late Relapse Risk in Diffuse Large B-Cell Lymphoma
Fewer patients who experienced late relapse received upfront rituximab compared with patients who experienced early relapse.
Carbapenem Reduces Tumor Burden in Patients With Cutaneous T-Cell Lymphomas and Bacterial Infection
Antibiotic treatment with carbapenem for S. aureus infection was efficacious in patients with cutaneous T-cell lymphomas.
Real-World Data in the Era of Precision Medicine for Lymphoid Malignancies
The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.
Frontline Treatment Strategies and Therapeutic Options for Mantle Cell Lymphoma
In a review article, researchers discussed how to maximize treatment efficacy while minimizing adverse effects for patients with mantle cell lymphoma.
Rituximab With or Without Lenalidomide in First-Line Treatment of Follicular Lymphoma
Results from a phase 2 trial suggest that adding lenalidomide to follicular lymphoma treatment with rituximab may be efficacious.
Follow-Up S0816 Trial Results: PET-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma
Researchers reported follow-up data for patients with advanced-stage Hodgkin lymphoma evaluated for response with positron emission tomography scanning.
Concurrent Indolent Lymphomas in Diffuse Large B-Cell Lymphoma Do Not Worsen Clinical Outcomes
Patients with concurrent diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma were more likely to have germinal center B-cell-like DLBCL.
Relapsed Follicular Lymphoma: Stem Cell Transplantation in the Era of Targeted Therapies
Both autologous and allogeneic stem cell transplantation have shown benefits in patients with relapsed follicular lymphoma, but long-term data are lacking.
Subtype of CXCR4 Mutation Correlated With Inferior Response to Ibrutinib in Waldenström Macroglobulinemia
Nonsense mutations in CXCR4, but not frameshift mutations, were associated with poor response compared with no mutation in CXCR4.
Current and Prospective Treatment Strategies for Follicular Lymphoma
In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.
Diagnostic Delay in Diffuse Large B-Cell Lymphoma Linked to Poorer Outcomes for Patients With Worse Disease
Researchers evaluated whether time to diagnosis of diffuse large B-cell lymphoma was associated with prognosis and survival.
HIV-Induced Expression of PD-L1 on Regulatory B Cells May Promote AIDS-Related NHL
HIV-induced regulatory B cells may inhibit T cell function through multiple mechanisms, potentially driving lymphomagenesis.
Increased Risk for Second Malignancy After Multiple Lines of Treatment in Follicular Lymphoma
Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.
Factors Associated With Long-Term Fatigue in Non-Hodgkin Lymphoma Survivors
Severe fatigue was more common in NHL survivors compared with the general population.
Pregnant Patients With Lymphoma Can Be Safely and Effectively Treated
Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Late Relapse Rates After Immunochemotherapy Treatment for Diffuse Large B-Cell Lymphoma
Patients who achieved event-free survival at 24 months following diagnosis were evaluated for late relapses.
Using a Risk-Based System to Predict Progression From Asymptomatic Waldenström Macroglobulinemia
The model stratified patients into 3 risk groups based on median time to disease progression.
Prospective Evidence Links Textured Breast Implants to Rare Lymphoma
The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
Current and Prospective Therapies for Double-Hit Lymphoma
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Response Patterns After Multiple Lines of Therapy in Mantle Cell Lymphoma
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
The Evolution of Frontline Hodgkin Lymphoma Treatment
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Ibrutinib Added to R-CHOP May Improve Outcomes for Patients Younger Than 60 Years
Though the primary survival endpoints were not met in this study, younger patients experienced improved outcomes with ibrutinib.
Combined Modality Therapy May Improve Overall Survival in Pediatric Hodgkin Lymphoma
Treatment for early-stage pediatric HL can include chemotherapy with or without radiotherapy, although use of radiotherapy is waning.
Autologous Stem Cell Transplantation Outcomes in Patients With Peripheral T-Cell Lymphomas
Patients with higher International Prognostic Index scores or advanced-stage disease experienced improved survival when treated with ASCT.
Improved Progression-Free Survival in Relapsed/Refractory Indolent Lymphoma With Lenalidomide Plus Rituximab
Patients with follicular or marginal zone lymphoma who received lenalidomide with rituximab experienced a median progression-free survival of 39.4 months.
Presence of Autoimmune Diseases May Increase Risk for Diffuse Large B Cell, Marginal Zone Lymphomas
The presence of rheumatologic conditions was also associated with variations in cancer site for both diffuse large B-cell lymphoma and marginal zone lymphoma.
Challenges Remain, New Therapies Needed for Pediatric Lymphoblastic Lymphoma
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Consensus Panel on Maintenance Therapies Following Autologous Hematopoietic Cell Transplantation in Lymphoma
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes
Presence of multiple mucosal sites at presentation in extranodal marginal zone lymphomas may predict poor survival outcomes.
Pentostatin, Cyclophosphamide, Rituximab for Indolent Non-Hodgkin Lymphomas
The combination of pentostatin, cyclophosphamide, and rituximab yielded comparable rates of survival and adverse events to other combination regimens.
Results From a Phase 2 Study Evaluating Ofatumumab for Advanced-Stage Follicular Lymphoma
Ofatumumab was well tolerated by patients with advanced-stage follicular lymphoma but did not appear superior to other monotherapy agents for this disease.
Palbociclib Plus Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Results from a phase 1 trial suggested that patients with previously treated mantle cell lymphoma may respond positively to ibrutinib plus palbociclib.
FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
A Novel Relapse Risk Stratification Model for Patients With Diffuse Large B-Cell Lymphoma
Researchers combined the International Prognostic Index with cell-of-origin subtype to identify patients at high risk for central nervous system relapse.
Updated WHO-EORTC Classification for Primary Cutaneous Lymphomas
Changes to the WHO-EORTC classification for primary cutaneous lymphomas were highlighted in a recent review article.
Dose-Adjusted Immunochemotherapy May Yield Durable Remission in Aggressive Diffuse Large B-Cell Lymphoma
Patients with MYC-rearranged aggressive diffuse large B-cell lymphoma appeared to achieve durable remission with EPOCH-R.
Researchers Report Early Clinical Promise for Macrophage Checkpoint Blockade
A doublet immunotherapy regimen incorporating the investigational mAb Hu5F9-G4 shows clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma.
CD19 CAR T-Cell Therapies: “Expect an Evolution”
“CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses,” according to Dr Michel Sadelin.
Improved Outcomes for Vitreoretinal Lymphoma With Combined Treatment
Patients who received combined systemic and intraocular treatment had longer failure-free and relapse-free survival.
CAR T Cell Therapy May Yield Durable Response in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Over half of evaluable patients who received an infusion of tisagenlecleucel achieved partial or complete response.
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
